胆囊良恶性病变组织中PARP和TRAP表达及其临床病理意义

Expressions of PARP and TRAP and their clinicopathological significances in the benign and malignant lesions of gallbladder

目的研究胆囊良恶性病变组织中聚腺苷二磷酸核糖聚合酶(PARP)和抗酒石酸酸性磷酸酶(TRAP)表达水平及其临床病理意义。方法EnVsionTM免疫组织化学法检测108例胆囊腺癌、46例癌旁组织、15例腺瘤性息肉和35例慢性胆囊炎组织中PARP和TRAP的表达。结果胆囊腺癌PARP和TRAP表达阳性率(57.4%、36.1%)明显高于癌旁组织(21.7%、4.3%)、腺瘤性息肉(6.7%、0)和慢性胆囊炎胆囊上皮(0、0)(P<0.01);PARP和TRAP表达阳性的良性病变胆囊上皮均呈不典型增生;高分化腺癌、肿块最大径<2cm、无淋巴结转移及未侵犯周围组织病例PARP和TRAP表达阳性率均明显低于中或低分化腺癌、肿块最大径≥2cm、淋巴结转移及侵犯周围组织病例(P<0.05或0.01);胆囊腺癌中PARP和TRAP表达水平呈高度一致性(χ2=7.17,P<0.01)。结论PARP和TRAP表达水平可能是反映胆囊腺癌发生进展、临床生物学行为及预后的重要酶类标记物。

Objective To investigate expressions of poly （ADP-ribose） polymerase （PARP） and tartrate resistant acid phosphatase （TRAP） and to detect their clinicopathologieal significanees in the benign and malignant lesions of gallbladder. Methods EnVisonTM immunohistochemistry was used for assaying the expressive levels of PARP and TRAP in paraffin-embedded sections from the specimens of adenoearcinoma （n = 108 ） , peritumoral tissues （n =46）, adenom- atous polyp （n = 15） and chronic eholeeystitis （n = 35）. Results The positive rates of PARP and TRAP were signifi- cantly higher in adenoeareinoma （57.4%, 36.1% ） than those in peritumoral tissues （21.7%, 4.3% ）, adenomatous polyp （6.7%, 0） and chronic choleeystitis （0, 0） （P 〈0. O1 ）. The positive benign cases of PARP and TRAP expression showed atypical hyperplasia of epithelium. The positive rates of PARP and TRAP were significantly lower in the well-differentiated adenoeareinoma, the maximal diameter of mass 〈 2 cm, no-metastasis of lymph node, and no-inva- siveness of regional tissues than those in the moderate-or poor-differentiated adenoeareinoma, the maximal diameter of mass t-2 em, metastasis of lymph node, and invasiveness of regional tissues （P 〈0.05 or 0.01 ）. The highly consistence was found between the expressive levels of PARP and TRAP in gallbladder adenocareinoma （X2 = 7. 17, P 〈 0.01）. Conclusion The expressive levels of PARP and/or TRAP may be important enzymatic markers for reflecting the carcinogenesis, progression, clinical biologic behaviors and prognosis of gallbladder adenocareinoma.